PTCT PTC Therapeutics (PTCT) Q1 FY26 earnings call
PTC Therapeutics reported a strong start to FY26, achieving record product revenue primarily driven by the robust global launch of Sephience, leading to an upward revision of full-year guidance. The company is also advancing its pipeline with positive interim data for votoplam in Huntington's disease and plans for a new vatiquinone study for Friedreich's ataxia. Management emphasizes leveraging its commercial infrastructure and strong cash position for continued growth and strategic business development.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
PTCT operating KPIs by quarter
| KPI | This call Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Patients Commercial | 1,244As of March 31, we had 1,244 commercial patients globally.Source: earnings call transcript | 1,647And as of June 30, we had 1,647 commercial patients on Sephience globally.Source: earnings call transcript | +32.4% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.